The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone after FOLFIRINOX (FFX) induction in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): Primary endpoint results of a randomized TEDOPAM GERCOR D17-01 PRODIGE 63 trial.
 
Anthony Turpin
Honoraria - AstraZeneca; BMS; Daiichi Sankyo/Astra Zeneca; Incyte; Merck; MSD Oncology; Norgine; SERVIER
Travel, Accommodations, Expenses - AstraZeneca; Merck; Pierre Fabre
 
Emmanuel Mitry
No Relationships to Disclose
 
Olivier Bouche
Consulting or Advisory Role - Amgen; Apmonia Therapeutics; Astellas Pharma; Deciphera; MSD Oncology; Pierre Fabre; SERVIER; Takeda
Speakers' Bureau - Amgen; Deciphera; Merck Serono; MSD Oncology; Pierre Fabre; Servier
Travel, Accommodations, Expenses - Pierre Fabre; Servier; Takeda
 
Yves Rinaldi
Honoraria - Amgen Astellas BioPharma; VIATRIS
 
Christophe Borg
No Relationships to Disclose
 
Jean-Philippe Metges
Honoraria - Amgen; Beigene; BeiGene; Gilead Sciences; MSD Oncology; Pierre Fabre; Pierre Fabre
Consulting or Advisory Role - Bayer; BeiGene; BeiGene; MSD Oncology
Travel, Accommodations, Expenses - BeiGene; MSD Oncology
 
Gael Roth
No Relationships to Disclose
 
Thierry Lecomte
Consulting or Advisory Role - Amgen; Amgen; AstraZeneca; AstraZeneca; BMS; Chugai Pharma Europe; DECIPHERA; IPSEN; Merck Serono; Pierre Fabre; Sanofi; Sanofi; SERVIER
Research Funding - LEO PHARMA (Inst); Pierre Fabre (Inst)
Travel, Accommodations, Expenses - Ipsen; Servier/Pfizer
 
Christophe Tournigand
No Relationships to Disclose
 
Isabelle Trouilloud
Travel, Accommodations, Expenses - Deciphera; Sandoz; SERVIER
 
You Heng Lam
No Relationships to Disclose
 
Clélia Coutzac
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Merck Serono; MSD Oncology; SERVIER
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; SERVIER
Speakers' Bureau - Amgen; Merck Serono; SERVIER
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Mundipharma; Sandoz; SERVIER
 
François Ghiringhelli
Honoraria - roche
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Roche/Genentech; Roche/Genentech
 
Christophe Louvet
No Relationships to Disclose
 
Vincent Hautefeuille
Honoraria - Advanced Accelerator Applications; Amgen; Deciphera; Esteve; Ipsen; Merck KGaA; Novartis; Sanofi; SERVIER
Research Funding - Ipsen
Travel, Accommodations, Expenses - Amgen; Ipsen; Novartis; Pfizer; Sanofi
 
Aurélien Lambert
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca/MedImmune; Bayer; GlaxoSmithKline; Ipsen; Janssen; Merck KGaA; Merck Serono; Novartis; Pierre Fabre; Servier/Pfizer
Travel, Accommodations, Expenses - Merck KGaA; Pfizer
 
Marielle Guillet
No Relationships to Disclose
 
Marie-Line Garcia-Larnicol
No Relationships to Disclose
 
Julie Henriques
No Relationships to Disclose
 
Cindy Neuzillet
Stock and Other Ownership Interests - Cereus Biosciences
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Baxter; Boehringer Ingelheim; Bristol-Myers Squibb; Fresenius Kabi; Incyte; Merck; MSD; Mundipharma; Nestlé Health Science; Novartis; Nutricia; OncoSil; OSE Immunotherapeutics; Pierre Fabre; Roche; Sanofi; SERVIER; Theradial; Viatris
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Fresenius Kabi (Inst); Nutricia (Inst); OSE Immunotherapeutics (Inst); Roche (Inst); SERVIER (Inst); Viatris (Inst)